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Abstract
Soft-tissue sarcoma (STS) represent a rare tumor entity, accounting for less than 1% of adult malignancies. The
cornerstone of curative intent treatment is surgery with free margins, although the extent of the surgical approach
has been subject to change in the last decades. Multimodal approaches usually including radiation therapy have
replaced extensive surgical procedures in order to preserve functionality while maintaining adequate local control.
However, the possibility to apply adequate radiation doses by external beam radiation therapy (EBRT) can be
limited in some situation especially in case of directly adjacent organs at risk with low radiation tolerance.
Application of at least a part of the total dose via intraoperative radiation therapy (IORT) with a single fraction
during the surgical procedure may overcome those limitations, because radiosensitive structures can be moved out
of the radiation field resulting in reduced toxicity while the enhanced biological effectivity of the high single dose
improves local control. The current review summarizes rationale, techniques, oncological and functional outcomes
including possible pitfalls and associated toxicities based on the published literature for IORT focusing on extremity
and retroperitoneal STS. In extremity STS, combination of limb-sparing surgery, IORT and pre- or postoperative EBRT
with moderate doses consistently achieved excellent local control rates at least comparable to approaches using
EBRT alone but usually including patient cohorts with higher proportions of unfavourable prognostic factors.
Further on, IORT containing approaches resulted in very high limb preservation rates and good functional outcome,
probably related to the smaller high dose volume. In retroperitoneal STS, the combination of preoperative EBRT,
surgery and IORT consistently achieved high local control rates which seem superior to surgery alone or surgery
with EBRT at least with regard to local control and in some reports even to overall survival. Further on, preoperative
EBRT in combination with IORT seems to be superior to the opposite combination with regard to local control and
toxicity. No major differences in wound healing disturbances or postoperative complication rates can be observed
with IORT compared to non-IORT containing approaches. Neuropathy of major nerves remains a dose limiting
toxicity requiring dose restrictions or exclusion from target volume. Gastrointestinal structures and ureters should be
excluded from the IORT area whenever possible and the IORT volume should be restricted to the available
minimum. Nevertheless, IORT represents an ideal boosting method if combined with EBRT and properly executed
by experiences users which should be further evaluated preferably in prospective randomized trials.
Background
Soft tissue sarcomas (STS) represent a rare tumor entity,
accounting for <1% of adult malignancies [1]. The ma-
jority (~60%) are located in the extremities, followed by
trunk and retroperitoneal space [2–4]. Surgery with
negative margins remains the cornerstone of curative
intent treatment, although the extent of the surgical ap-
proach has been subject to change in the last decades.
Modern treatment concepts in oncology do not only
focus on the achievement of local control (LC) and over-
all survival (OS) but also on preservation of functionality
and quality of life [5, 6]. Therefore multimodal organ-
and/or function-preserving concepts have increasingly
replaced extensive surgical procedures (for example am-
putations). Within such approaches less extensive sur-
gery with much smaller margins is used resulting in
improved functional outcome, but with the need for
additional local treatment modalities (usually radiation
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therapy) to maintain adequate LC. However, in some sit-
uations the possibility to achieve LC by additional radi-
ation therapy (RT) can be limited. This is especially true,
if adequate doses cannot be applied by external beam ra-
diation (EBRT) alone without considerable risk of severe
side effects to surrounding normal tissue, counteracting
the aim of the function-preserving overall approach. Ap-
plication of at least a part of the total dose via intraoper-
ative radiation therapy (IORT) with a single fraction
during the surgical procedure might be beneficial in
such situations, because radiosensitive structures can be
moved out of the radiation field resulting in reduced
toxicity while the enhanced biological effectivity of the
high single dose improves local control [7–14]. Although
STS of different body regions histologically represent the
same tumor entities, there are distinct differences in out-
come especially between extremity and non-extremity
sarcomas [15]. Based on the favourable anatomical situ-
ation with less vital structures directly adjacent to the
tumor, extremity lesions can usually be resected with
much wider margins and surgery results less frequently
in residual disease as in other sites, leading to a generally
lower rate of local recurrences [15]. Additional radiation
is also more limited in non-extremity regions due to
nearby structures with low radiation tolerance and sal-
vage surgery in case of local recurrence is also less fre-
quently possible in non-extremity lesions leading to a
higher impact of achieving LC in those sites with regard
to OS and long-term morbidity [15]. Therefore this re-
view will separately discuss IORT for extremity and non-
extremity lesions, focusing on the retroperitoneal space
for the latter part. Regarding the literature dealing with
IORT in STS, some general aspects have to be kept in
mind: For several decades, IORT was available only at a
small number of major centers. Therefore randomized
or prospective studies on IORT for STS are very rare.
Most evidence is based on rather small retrospective
analyses with comparably short follow up. Because of
the rarity of the disease per se most reports further com-
prise inhomogeneous cohorts of patients. Therefore
comparison of IORT series and non-IORT series is
sometimes difficult, although one should be aware that
IORT is usually used in patients with rather unfavour-
able prognostic factors similar to EBRT prior to its im-
plementation as a standard procedure.
Technique of IORT
Intraoperative radiation therapy is defined as the appli-
cation of a single fraction of high dose irradiation during
surgery. The target volume usually includes the tumor
bed after gross total resection or the remaining disease if
gross complete resection was not achieved. Usually
IORT is used as a boost preceeded or followed by EBRT.
Its sole application should be restricted to situations
after prior irradiation. An IORT boost offers (at least
theoretically) some advantages compared to an EBRT
boost: first of all, radiosensitive structures or organs at
risk can be effectively spared from radiation exposure by
moving them surgically out of the radiation field. The
risk for a geographical miss is minimized because target
volume definition takes place under visual control. As
no substantial intra- or interfractional movements have
to be compensated, safety margins can be kept to a
minimum and finally overall treatment time is short-
ened. These advantages have to be weighed against some
drawbacks: Usually the final pathological margin will not
be available for treatment stratification and the use of a
high single dose might result (at least theoretically) in
increased late toxicity. Three-dimensional treatment
planning is not (yet) available, exact treatment documen-
tation can be challenging and finally doing IORT is still
a major interdisciplinary effort and therefore only avail-
able at large centers [16].
Technically, two major approaches are in use for IORT
treatments of STS: electrons and HDR-brachytherapy.
Electrons (IOERT) can be applied either by dedicated
conventional LINACs mounted in specialized operation
rooms or more recently by small mobile LINACs specif-
ically invented for IORT. After surgical removal of the
tumor, the target volume is defined by the radiation on-
cologist in correspondence with the treating surgeon.
Uninvolved radiosensitive tissues can be displaced or
covered by lead shielding. An applicator of appropriate
size is chosen, manually positioned and attached to the
table (see Fig. 1). Applicators are made of steel or plastic
to restrict the radiation field laterally and are usually
available in different sizes, shapes and bevel angles. Prior
to irradiation, the axis of the applicator has to be aligned
properly with axis of the LINAC in a defined distance.
This can be achieved either by direct linkage between
the applicator and the LINAC (so-called hard-docking)
or by using a laser-beam guidance system without direct
contact between applicator and LINAC (so called air-
docking). Most of the LINACs in use are capable of
delivering 4–12 MeV electrons (some achieve even 15–
20 MeV), thus covering tissue depths of up to 4 cm. The
dose is usually prescribed to the 90% isodose. In case of
large target volumes, several adjacent applicators might
be used. Care should be taken regarding fluids covering
the tissue surface or tissue inhomogeneities [16]. An-
other opportunity is the use of HDR-Brachytherapy. The
procedure regarding tumor removal, target volume def-
inition and replacing of radiosensitive organs at risk is
very similar to the electron method. Instead of an elec-
tron applicator a so-called flab applicator is brought into
the operative situs. This usually consists of a flexible (at
least to some extent) silicone-based surface mold which
includes parallel source guide tubes in a defined
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distance. The applicator is directly attached to the tissue
surface of the target volume, usually fixed with sutures
and connected with the HDR remote afterloader. Dwell
positions and times are calculated usually based on tabu-
lated values. Dose is generally prescribed at the center of
the target to a 0.5 cm depth. Due to the very steep dose
fall-off, only tissue depths of 0.5-1 cm can be adequately
covered with this technique, however it offer benefits
especially if large irregular surfaces have to be covered
[16, 17]. Dose concepts are similar between electrons
and HDR-brachytherapy. Usually a dose of 10–20 Gy is
applied in a single faction. However, the exact conver-
sion of high single doses into biologic equivalent doses
in fractionated therapy is still a matter of debate. Using
the linear-quadratic equation as the most recognized
model, a single dose of 15 Gy would be equivalent to
31–54 Gy in conventionally fractionated RT assuming
alpha/beta values of 3–10 for tumor and late reacting
tissue response [18, 19]. However the model is not val-
idated for high single doses and its use may result in
an overestimation of the equivalent fractionated dose
[20, 21]. Further on, the possibility of a direct conver-
sion should be questioned given the growing evidence
for a different tissue reaction to high single doses per
se if a threshold of 8–10 Gy is exceeded [22]. Based on
alternative models [21] and the clinical experience, it
seems more reliable to assume an equivalent fraction-
ated dose which is 2–3 fold the IORT dose. Because
the tumor effect seems rather 2 fold and the late react-
ing tissue effect rather 3-fold, organs at risk should be
optimally spared and IORT should be combined with
EBRT whenever feasible.
Rationale for IORT in extremity sarcoma
Since Rosenberg et al. [23] showed similar overall sur-
vival comparing amputation with limb sparing surgery
followed by RT, the combination approach has emerged
as the standard of care in extremity sarcomas with high
risk features. Subsequent randomized trials [24] and
large scale population based analyses [25] have clearly
confirmed that postoperative EBRT leads to improved
local control in all subgroups. More recently, preopera-
tive EBRT has been proven to be equally effective in
terms of LC and OS compared to postoperative EBRT in a
randomized trial [26]. However, additional EBRT comes
along with increased toxicity. In the postoperative setting,
high doses of ≥60 Gy must be applied to large volumes,
which can be associated with marked acute and late toxic-
ities and consequently result in unfavourable functional
outcomes [27]. In the preoperative setting lower rates of
late toxicity have been described [26, 28], which seems to
be mainly based on the opportunity to use lower doses
and smaller treatment volumes [28]. However, the im-
provement in late toxicity had to be paid with doubled
rates of severe wound complications [26, 28]. The intro-
duction of IORT could offer a smart way out as advocated
by several groups [5, 6, 29]. Replacement of the EBRT
boost phase by an IORT boost would not only result in
smaller treatment volumes because safety margins for
daily positioning errors can be omitted, but also in the
possibility to exclude organs at risk like major nerves or
skin from the radiation field which could at least theoret-
ically reduce late toxicities and improve long term func-
tional outcome. If applied prior to postoperative EBRT
with moderate doses, this might avoid an increased wound
complication rate and therefore would combine this ad-
vantage of the postoperative approach with the smaller
treatment volumes known to be beneficial from the
preoperative setting [29, 30].
IORT Series in extremity sarcomas
IORT has been introduced into the treatment of extrem-
ity STS in the mid 80s at several US centers [31, 32]. For
example, Petersen et al. [32] described the initial experi-
ence at Mayo Rochester reporting on 91 patients with
limb girdle or extremity STS, which have been treated
between 1986 and 1995 with IOERT as a component of
therapy. With a median follow-up (f/u) of 3 years,
IOERT achieved excellent 3-year LC and OS rates of
92% and 76%, which were at least comparable if not su-
perior to the results achieved with EBRT alone. Disease
status (primary vs recurrent) significantly impacted LC
Fig. 1 Example of IORT in extremity sarcoma
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(95% vs 81%, p = 0.014) but not OS. Toxicity was pro-
spectively scored according to NCI-IORT criteria with a
special focus on neuropathy. Severe neuropathy was ob-
served only in 2% of the patients while 10% developed a
moderate form. In the late 80s/early 90s, also some
major european centers mainly from Spain (Pamplona,
Madrid) and Germany (Heidelberg, Munich) started to
use IORT for extremity STS (see Fig. 1). In the following
two decades a variety of retrospective single center experi-
ences with only slightly different approaches and similar
outcomes have been published (summarized in Table 1)
[5, 6, 32–37]. Patient numbers were rather small although
most series had mature follow-up (median 33–93 months)
[5, 6, 32–36]. Consistently, the cohorts included large pro-
portions of patients with rather unfavourable prognostic
factors. For example the rates of R1 resections (usually in
the range of 0–25% in non-IORT series) ranged from 17
to 58% [5, 6, 32–37]. Treatment approaches were similar,
mainly consisting of 10–20 Gy IORT preceeded or
followed by EBRT with 40–50 Gy. With regard to the
unfavourable patient cohorts, they consistently reported
excellent 5-year-LC rates of 83–90% [5, 6, 35, 36] and 5-
year-OS rates of 66–83%, respectively [5, 6, 33, 35, 36].
Moreover, they reported excellent rates (83–100%) of
limb preservation [5, 6, 33–36] and good/excellent
functional outcome (59–86%) in the vast majority of
patients [5, 6, 34, 36]. For example Azinovic et al. [34]
treated 45 patients with extremity sarcomas mainly lo-
cated in the lower limb (82%). 19 (42%) were already in
recurrent situation and wide negative margins could be
achieved only in 67%. IOERT was administered with a
median dose of 15 Gy using mainly 6–9 MeV electrons.
36 patients received postoperative EBRT with 40–
50 Gy. With a remarkable median follow-up of 93 months,
they reported a crude LC rate of 80%. Surgical margins
(5y-LC 87% negative vs 57% positive) and disease situation
(5y-LC 88% primary vs 60% recurrent) correlated signifi-
cantly with LC, while OS was impacted only by disease
situation (7-year OS 75% primary vs 47% recurrent). Tox-
icity was scored according to CTCAE 2.0. Postoperatively
delayed wound healing or soft tissue necrosis was found
in 18%. Acute radiation toxicity was generally mild and re-
stricted to skin (grade 2–3: 20%). Late toxicity included
neuropathy in 5 cases (11%), fracture in 2 (4%), symptom-
atic fibrosis in 2 (4%) and edema in 2 (4%). The risk for
neuropathy was 25% in those with the nerve included into
the IOERT field and 11% if not. Median time to neur-
opathy was 13 months, three of 5 patients showed at least
partial recovery after 12 months of duration. Amputation
was needed in 5 patients (3 due to toxicity, 2 due to recur-
rence) resulting in a limb preservation rate of 88%. 31 pa-
tients were evaluable for functional outcome of whom 21
(77%) showed no or only minor impairment. Oertel et al.
[6] reported another large single center series from the
University of Heidelberg. They included 153 patients of
whom 25 had resectable distant spread at time of surgery.
92% showed high grade lesions and 50% were larger than
10 cm. 38% were already in recurrent situation and wide
negative margins could be achieved only in 49% while 15%
even showed gross residual disease. With a median
follow-up of 33 months, they reported a 5-year LC and
OS rate of 83% in the 128 patients without known distant
spread at time of surgery. LC was significantly affected by
resection margin and IOERT dose ≥ 15 Gy, while OS was
associated with resection margin, grading and IOERT
dose. Interestingly, 30% of the local recurrences were
Table 1 Results of major IORT series in extremity sarcoma
Author Year Type n f/u R0 IORT EBRT 5y-LC 5y-OS LP FC
Petersen [32] 1999 r,sc 91 34 n.r. 10–15 45–50 92b 76b n.r. n.r.
Edmonson [33] 2001 r,sc 39 70 62 10–20 45 90a 80 95 n.r.
Azinovic [34] 2003 r,sc 45 93 67 15 45–50 80a 64a 88 77
Kretzler [5] 2004 r,sc 28 52 61 12–15 50 84 66 100 59
Oertel [6] 2006 r,sc 128c 33 49 15 45 83 83 90 86
Llacer [35] 2006 r,sc 79 58 42 20 (LDR) 45–50 90 69 100 n.r.
Alvarez [36] 2008 r,sc 53 66 n.r. 7.5–12.5 n.r. 87 75 83 81
Callister [37] 2008 r,sc 48 20 83 10–15 50 83b 84b n.r. n.r.
Roeder [29] 2013 p,sc 34 43 88 10–15 40–50 97 79 94 81
Calvo [40] 2014 r,mc 159 67 84 12.5 45 82 72 94 n.r.
Roeder [30] 2015 r,sc 183 64 68 15 45 86 71 95 83
Roeder [39] 2015 r,mc 259 63 71 12 45 86 78 95 81
year year of publication; type type of study; r retrospective; p porspective; sc single-center; mc multi-center; n number of patients; f/u median follow up in months;
R0 rate of microscopic complete resections in %; IORT intraoperative radiation therapy dose in Gy (median or range); LDR low dose rate brachytherapy; EBRT external beam
radiation therapy dose in Gy (median or range); 5y-LC estimated 5-year-local control rate in %; 5y-OS estimated 5-year-overall survival rate in %; LP limb preservation rate in
%; FC rate of excellent/good functional outcome in %; a: crude rates, b: estimated 3-year rates, c: excluding patients with distant metastases at time of surgery
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found clearly outside the EBRT fields and 40% were
judged as marginally while only 10% were located infield-
IOERT. They further reported a limb preservation rate of
90% with good functionality defined as impairment not
interfering with activities of daily living (ADL) in 86%.
Acute toxicity CTCAE 2.0 grade ≥ 2 was observed in 23%
(mainly wound healing disturbances) and late toxicity
RTOG grade ≥ 2 occurred in 17% including neuropathy in
5%, fibrosis/joint stiffness in 5%, edema in 4% and ulcer-
ation in 3%. Callister et al. [37] reported the updated Mayo
Arizona experience including 48 patients treated with pre-
operative EBRT (median dose 50 Gy) followed by surgery
and IOERT (median dose 10–15 Gy, 6–9 MeV). Free mar-
gins were achieved in 40 patients while microscopically
positive margins remained in 8 patients. With a median f/
u of 31 months they observed 3-year LC and OS rates of
89% and 75%. Severe postoperative wound complications
were found in 16 patients (33%).
Because of the known limitations of the mentioned
retrospective analyses, some groups recently focused on
different approaches to evaluate IOERT in extremity
STS, namely restricted cohorts, prospective evaluations
or pooled analyses. Researchers from the University of
Heidelberg recently updated their experience but strictly
restricted their analysis to patients with extremity (not
limb girdle) STS as defined according to WHO, who had
received gross complete resection with documented
margin and additional EBRT in conventional fraction-
ation with suitable RT documentation available [30].
One hundred eighty-three patients met the inclusion cri-
teria of whom 78% presented in primary situation,
mainly located in the lower limb (80%). The majority
showed high grade lesions (95%) with advanced stages
(IIB-IV:70%). Median IOERT dose was 15 Gy and me-
dian EBRT dose 45 Gy. IOERT dose was usually re-
stricted to 10–12 Gy if major nerves had to be included.
Median electron energy was 6 MeV. Surgery resulted in
free margins in 68% while 32% had microscopically in-
volved margins. With a median follow up of 64 months,
the estimated 5- and 10-year LC rates were 86 and 84%.
LC was significantly affected by resection margin (5y-LC
92% R0 vs 75% R1) and disease situation (5y-LC 90%
primary vs 74% recurrent) in univariate analysis, but
only disease situation remained significant in multivari-
ate analysis. The estimated 5- and 10-year OS rates were
77 and 66%. OS was significantly associated with grad-
ing, metastases prior/at IOERT and stage in univariate
analysis, but only grading and metastases at/prior to
IOERT remained statistically significant on multivariate
analysis. Toxicity was scored according to CTCAE 3.0.
Postoperative complications were documented in 19%,
mainly as wound complications. Severe acute radiation
side effects were rare (1%), while severe late effects were
scored in 20%. This included neuropathy in 8% and
fractures in 6%. Secondary amputations were needed in
9 patients, transferring into a limb preservation rate of
95%. Preserved limb function without impairment of ac-
tivities of daily living was observed in 83%. The authors
concluded that IOERT resulted excellent oncological
and functional outcome.
The same group recently published also prospective
data from a small trial (50 pts) including IOERT as part
of local treatment for STS [29, 38]. This single arm study
(NeoWTS trial, Clinical Trials.gov NCT01382030,
EudraCT 2004-002501-72) evaluated the use of neoadju-
vant and adjuvant chemotherapy additionally applied to
local treatment in high risk sarcomas. Local treatment
included limb-sparing surgery, IOERT and postoperative
EBRT. The subgroup of 34 patients with extremity le-
sions was evaluated separately focusing on local effects
[29]. Surgery resulted in free margins in 88% and micro-
scopically positive ones in 12%. Median IOERT dose was
15 Gy and median EBRT dose 46 Gy. With a median f/u
of 48 months only one local recurrence was observed,
transferring into an estimated 5-year LC rate of 97%.
Overall survival was also excellent (5-year rate 79%).
Postoperative wound complications occurred in 20%,
acute radiation toxicity was generally mild (no grade 3
CTCAE 3.0). Severe late toxicity (CTCAE 3.0) was found
in 18%, including only one patient with neuropathy and
only one with fracture. Regarding all grades of neur-
opathy, the rate was 12% in all patients but increased to
25% if only patients with major nerves included into the
IOERT area were considered. The final limb preservation
rate was 94%. Functional outcome was assessed at differ-
ent time points in evaluable patients. The cumulative in-
cidence of impairment interfering with ADL including
amputation was 83% at one year and 77% at two years.
Another idea to improve evidence for IOERT in ex-
tremity sarcoma was to perform pooled analyses of pa-
tients from several expert centers. Two groups have
performed pooled data analyses so far [39, 40]. The first
one, recently published by Calvo et al. [40], included 159
patients from three Spanish expert centers. All presented
in primary situation without distant spread. Surgery had
resulted in close (<1 cm) or microscopically positive
margin but was grossly complete in all patients. IOERT
was performed with a median dose of 12.5 Gy and com-
bined with pre- or postoperative EBRT using a median
dose of 45 Gy. Median electron energy was 6 MeV. With
a median follow-up of 53 months (4–316), the crude
local relapse rate was 16%, transferring into estimated 5-
and 10-year LC rates of 82% and 81%. 24% of the recur-
rences were outfield IOERT, resulting in 5- and 10-year
central control (infield IOERT) rates of 86% and 85%.
Resection margin (R1) was significantly associated with a
higher risk for local and infield recurrence. IOERT dose
>12.5 Gy was further associated with improved infield
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IOERT control. Interestingly this effect seemed to be re-
stricted to patients with free margins. Estimated OS at 5
and 10 years was 72 and 64%, significantly associated with
age and stage. Severe acute toxicity (RTOG grade ≥ 3) was
described in 14% mainly as skin reactions and wound
healing disturbances. Severe late side effects (RTOG
grade ≥ 3) were reported in 10%, mainly neuropathy.
The second pooled analysis, which has been recently
published in abstract form [39], included patients from
three european centers (Heidelberg, Madrid, Aviano).
After a first attempt including 320 patients, which had
been presented at the ISIORT meeting 2008 in Madrid
[41], the authors decided to tighten the inclusion criteria
similarly to the above mentioned latest series from
Heidelberg because of large inhomogeneities in the
cohort. The actual analysis, presented at the ISIORT
meeting 2015 in Barcelona [39], comprises 259 patients
with extremity STS (as defined by WHO criteria) who
received at least gross complete resection, IOERT and
additional EBRT. The cohort includes 20% patients
already in recurrent situation and 29% patients with
microscopically positive margins. Median IOERT dose
was 12 Gy and median EBRT dose 45 Gy. With a me-
dian follow up of 63 months, the crude local failure rate
was 10%, transferring into an estimated 5-year LC rate
of 86%. Resection margin (5-year LC 94% R0 vs 70% R1)
and disease situation were significantly associated with
LC in univariate analysis, but only resection margin
remained significant on multivariate analysis. Estimated
5-year OS was 78%, which was significantly influenced
only by grade and stage IV prior or at IOERT. Secondary
amputations were needed in 5%, mainly due to recur-
rence. Functional outcome was rated as good (not inter-
fering with ADL) in 81% including and 86% excluding
amputations.
In summary, the combination of limb-sparing surgery,
IORT and EBRT resulted consistently in excellent 5-year
LC rates of 82–97% [5, 6, 29, 30, 35, 36, 39, 40] in patients
with extremity STS. Those results are at least equal to
major Non-IORT series, which consistently report 5-year
LC rates of 83–93% [15, 42–50], especially if the higher
proportions of patients with unfavourable prognostic fac-
tors in the IORT series are taken into account. Beside
from oncological outcome, IORT containing approaches
resulted consistently in very high limb preservation rates
(83–100%) [5, 6, 29, 30, 33–36, 39, 40] with good func-
tional outcome (59–86%) [5, 6, 29, 30, 34, 36, 39]. This
might be attributed to the smaller high dose volume com-
pared to an EBRT boost as treatment volume was clearly
associated with increased late toxicity in a randomized
trial using EBRT alone [28]. Some questions regarding
supposed and actual IOERT-associated toxicities should
be additionally addressed: Postoperative complications, es-
pecially wound complication rates are similar in IORT-
and Non-IORT containing approaches. In the largest sin-
gle center series from Heidelberg, postoperative complica-
tions (CTCAE 2.0) were found in 18% of the patients
using mainly postoperative EBRT [30]. In the prospective
trial, postoperative complications of all grades (CTCAE
3.0) were found in 20% of whom only 9% were grade 3
using a similar approach [29]. Calvo et al. [40] observed
an even lower rate of 5% wound complications in their
pooled analysis and Kunos et al. [51] found a 15% rate if
IOERT was combined with postoperative RT and 36% if
IOERT was combined with preoperative IOERT. Those
figures almost exactly equal the numbers from the NCIC
trial comparing preoperative and postoperative EBRT
without IORT, which reported 35% in the preoperative
and 17% in the postoperative arm [26] using almost iden-
tical definitions of wound complications. Thus, it seems
unlikely that IOERT increases the wound complication
rate per se. Second, neuropathy has been considered as a
dose limiting late toxicity for IORT containing approaches
based on the experience from other body regions [52].
However Roeder et al. [29] observed 12% neuropathy of
all grades (CTCAE 3.0) including only 3% grade 3 in their
prospective subgroup analysis. Azinovic et al. [34] found
11% neuropathy in total in their series and Calvo et al.
[40] reported a 3% RTOG grade 3 neuropathy rate in their
pooled analysis. These neuropathy rates seem lower than
historical reports from other body regions which might be
attributed to the fact that most of the expert centers try to
exclude major nerves from the IORT area in extremity
sarcoma whenever possible. If only the patients are con-
sidered in whom major nerves have been included into
the IORT fields, the rates of neuropathy (all grades) in-
creased to 25% in both series by Roeder et al. [29] and
Azinovic et al. [34] including a nearly three-fold increase
in grade 3 neuropathies. Although not shown in the men-
tioned series, the dose-dependency of neuropathy has
been established for IORT long ago in other body sites.
Gundersson et al. [53] described 3% NCI-IORT grade 2/3
neuropathy with IORT doses ≤12.5 Gy compared to 21%
with ≥ 15 Gy in a series of patient with colorectal cancer.
Haddock et al. [54] recently confirmed a significant in-
crease in neuropathy if a treshold dose of 12.5 Gy is
exceeded. Therefore major nerves should be excluded
from the IORT field whenever feasible or the dose should
be limited ≤12.5 Gy. On the other hand one has to keep in
mind that the alternative with regard to treatment radical-
ity would be to sacrifice the corresponding nerve surgi-
cally in most of the mentioned situations, which would
results in a severe neuropathy rate of 100%. Finally, IORT
might result in increased fibrosis. Van Kampen et al. [55]
thoroughly analysed the association between fibrosis
(scored according to LENT-SOMA criteria) and IOERT
combined with EBRT in 53 patients. They found a 21%
rate of fibrosis of all grades and a 9% rate of severe
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fibrosis. In a subsequent Cox model only the IOERT vol-
ume was significantly associated with severe fibrosis.
While an IOERT volume of 200 ccm was associated with a
5% risk of severe fibrosis, the risk increased to almost 50%
if the volume was doubled. Thus, the IOERT volume
should always be limited to the possible minimum. How-
ever, IOERT as part of a multimodal approach offers excel-
lent outcomes in patient with extremity STS even in
prognostic unfavourable situations. IOERT is associated
with low acute and late toxicity and results in high
limb preservation rates with good functional outcome
if the mentioned issues are properly considered and
seem therefore beneficial compared to EBRT alone at
least in subgroups.
Rationale for IORT in retroperitoneal sarcoma
Similarly to extremity STS, surgery remains the corner-
stone of curative intent treatment in retroperitoneal sar-
coma [56, 57]. However, in contrast to extremity sarcoma,
local progression remains the dominant pattern of failure
with roughly 50–80% of the patients failing locally even
after gross total resection [52, 58–62]. Resection margin is
a strong prognostic factor [59–61] but wide margins are
usually not achievable [19, 56, 57, 60]. This builds up (at
least theoretically) an even stronger rationale for the
addition of radiation therapy than in extremity sarcoma.
But although retrospective comparisons consistently
show improved LC rates with the addition of radiation
[59, 60, 62], a clear survival benefit has not been proven
and a randomized comparison of combined modality
treatment vs surgery alone is still missing. Further on,
postoperative irradiation of the tumor bed is often lim-
ited by the tolerance of surrounding organs at risk [52].
Based on the experience in extremity STS and retro-
spective data, doses of 60–70 Gy would be needed in
the postoperative setting to achieve adequate LC especially
regarding the narrow surgical margins [19, 63, 64]. How-
ever, tumor cavities after resection of retroperitoneal STS
are usually large and subject to considerable inter- and
intrafractional movement. Applying such doses with the
generous safety margins known from extremity sarcoma
would result in excessive toxicity as the tolerance dose for
small bowel is only about 50–55 Gy in small volumes [52].
These limitations have led to an early interest in the use of
IORT in addition to postoperative radiation already in the
late 80s. The NCI conducted a small randomized trial
which compared the combination of an IOERT boost
(20 Gy) with moderately dosed postoperative EBRT (35–
40) Gy versus postoperative EBRT alone using 50–55 Gy
[52]. After inclusion of 35 patients and a medium follow
up of 8 years, they observed a significantly improved LC
rate of 60% vs 20% in favour of the IOERT arm. Late
gastrointestinal toxicity (scored according to NCI-IORT
criteria) was also significantly lower (13% vs 60%) but the
neuropathy rate was clearly increased (60% vs 5%) with
the use of IOERT. Several other groups have reported also
encouraging LC rates with the combination of IORT and
postoperative EBRT in retrospective single-center analyses
[19, 65, 66]. For example Alektiar et al. [66] reported on
32 patients, of whom 23 had been enrolled in a phase I/II
trial evaluating the combination of 12–15 Gy HDR-IORT
followed by EBRT with 45–50.4 Gy and 9 patients had
been treated accordingly but off protocol. About two
thirds of the patients suffered already from recurrent dis-
ease, the majority had high grade tumors and the most
common histology was liposarcoma. Gross total resection
was achieved in 30 patients, while the remaining two had
minimal gross residual disease. They observed an encour-
aging 5-year local control rate of 62% and a 5-year overall
survival of 45%. The overall complication rate (scored
according to NCI-IORT criteria) was 34%, mainly repre-
sented by gastrointestinal obstruction (18%) and fistula
formation (9%), while the rate of neuropathy was only 6%.
However, with a closer look to the reported results,
central (infield IORT) local control was usually much
higher than overall local control. For example Krempien
et al. [19] analysed 67 patients who had been treated
with IORT with or without additional postoperative
EBRT at the University of Heidelberg. Rates of chronic
gastrointestinal toxicity (10%), neuropathy (8%) and ur-
eteral stenosis (3%) scored according to RTOG criteria
were considerably low, and although most patients
showed microscopically incomplete resection (51%) and
18% even suffered from gross residual disease, they
observed a 5-year central control rate (infield IORT) of
72%. However, regarding local control (defined as re-
growth or progression inside the abdominal cavity) the
5-year rate dropped to only 40%, indicating that many
local failures did not occur in the high risk region cov-
ered by IORT but in the adjacent low risk region. Thus,
the combination of IORT and EBRT seemed effective
in sterilizing the high risk region in most of the pa-
tients, but postoperative EBRT alone seemed not able
to control residual disease in the adjacent low risk re-
gions probably due to the known limitations in dose
and target volume coverage. This raised the question
if preoperative radiation with or without IORT might
be beneficial.
Compared to the postoperative approach, preoperative
radiation therapy can offer several benefits, including a
more precise target volume definition with smaller safety
margins, reduced dose to adjacent organs at risk because
of their displacement through the tumor itself, a possible
devitalisation of tumor cells prior to surgery, fibrosis and
thickening of the pseudocapsule, at least moderate
tumor shrinkage and the avoidance of treatment delays
due to postoperative complications [56, 58, 67]. This
should result at least theoretically in less toxicity due to
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reduced doses in adjacent organs at risk but increased local
control due to a more adequate target coverage which
could be further enhanced by an intraoperative boost.
Several groups have evaluated combinations of pre-
operative and intraoperative radiation therapy and consist-
ently reported high local control rates with acceptable
toxicities (see Table 2) [57, 67–73]. For example Petersen
et al. [57] reported the Mayo experience with 87 patients,
who have been treated with preoperative EBRT (mainly
45–50 Gy) followed by maximal resection and IOERT
(median dose 15 Gy). About half of the patients presented
already in recurrent situation, mainly with large (median
size 10 cm) high grade tumors (62%). Most patients had at
least microscopically incomplete resections (64%) while
17% showed even gross residual disease. Nevertheless,
they observed an encouraging 5-year LC rate of 59% and a
5-year OS rate of 48%. Resection margin had a strong
impact on local control and overall survival. Severe
gastrointestinal toxicity (scored according to modified
NCI-IORT criteria) was found in only 18% and severe
neuropathy in only 10% of the patients. To further
evaluate the benefit of IORT after preoperative EBRT
and surgery several retrospective comparisons have
been performed but resulted in inconsistent findings.
Gieschen et al. [68] reported on 29 patients from
MGH, who had received preoperative EBRT (median
45 Gy) and gross complete resection and were treated
either with 10–20 Gy IORT or no further therapy.
They observed a clearly improved 5-year LC rate of
83% with IORT compared to 61% in patients without
IORT. Moreover they described a significantly differ-
ent 5-year OS rate of 74% vs 30% favouring patients
with additional IORT treatment. An update of the
MGH experience published by Pierie et al. [69], which
included 62 patients receiving preoperative EBRT
followed by surgery with/or without IORT confirmed
the results of the initial analysis. The group who re-
ceived additional IORT showed a 5-year OS of 77%
compared to 45% in patients without IORT. Accord-
ing to multivariate analysis, IORT was an independent
prognostic factor regarding both local control and
overall survival. In contrast, Ballo et al. [71] did not
observe a significant benefit for the addition of IORT
in their analysis of 82 patients who had received pre-
(60%) or postoperative EBRT (40%) and gross com-
pete resection. They reported a 5-year LC rate of 51%
in the IORT group compared to 46% the non-IORT
group. According to multivariate analysis, resection
margin and primary vs recurrent situation were iden-
tified as strong prognostic factors for local control.
However, those factors were clearly overrepresented
in the (much smaller) IORT group (R1: 61% vs 43%,
recurrent situation 40% vs 25%), and therefore a bias
cannot be fully ruled out.
Table 2 Results of major series IORT series in retroperitoneal sarcoma
EBRT IORT
Author Year Type n f/u GTR pre post dose % dose 5y-LC 5y-OS
Sindelar [62] 1993 p,sc 15 96 100 - 100 35-40 100 20 601 452
ran 20 100 - 100 50-55 - - 201 522
Alektiar, [66] 2000 r,sc 32 33 94 - 78 45-50 100 12-15 62 45
Gieschen [68] 2001 r,sc 16 38 100 100 - 45 100 10-20 83 74
13 100 100 - 45 - - 61 30
Petersen [57] 2002 r,sc 87 42 83 75b 28b 48 100 15 59 48
Bobin [76] 2003 r,sc 24 53 92 29 63 45-50 100 15 461 56
Krempien [19] 2006 r,sc 67 30 82 - 67 45 100 15 403 64
Pierie [69] 2006 r,sc 14 27 100 100 40-50 100 10-20 n.r. 77
27 100 100 40-50 - - n.r. 45
Pawlik [70] 2006 p,mc 72 40 75 100 - 45 47 15 604 50
Ballo [71] 2007 r,sc 18 47 100 60 40 45-66 100 15 51 n.r
63 47 100 45-66 - - 46 n.r
Sweeting [72] 2013 r,sc 18 43 100 94 - 45 100 10-20 64 72
Gronchi [73] 2014 r,mc 83 58 84 88 - 50 17 12 631,5 59
Roeder [67] 2014 p,sc 27 33 96 100 - 45-55 85 12 72 74
year year of publication; type study type; p prospective; r retrospective; ran randomised; sc single center; mc multicentre; n number of patients; f/u median follow-up in
months; GTR percentage of patients in whom gross total resection was achieved; pre percentage of patients with preoperative EBRT; post percentage of patients with
postoperative EBRT; dose EBRT dose in Gy (median or range); IORT intraoperative radiation therapy; % percentage of patients who received; IORT dose: dose of IORT
in Gy (media or range); 5y-LC estimated 5-year local control in rate if not otherwise specified; 5y-OS estimated 5-year overall survival if not otherwise specified; n.r. not
reported; 1: crude rate; 2: median OS in months; 3: abdominal control; 4: in grossly resected patients; b: 14% received both (pre- and postop. EBRT with lower doses
(included in pre- and postop figures); 11% received no EBRT; 5: in resected patients
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The combination approach is further currently evalu-
ated in a prospective single arm trial (Retro-WTS trial,
Clinical trial number NCT01566123, see Fig. 2) at the
University of Heidelberg [56, 67]. Patients are eligible if
they suffer from retroperitoneal sarcoma of any grade
with a size ≥5 cm, are free of distant metastasis and
deemed at least marginally resectable. Treatment con-
sists of preoperative intensity-modulated image-guided
radiation therapy using the simultaneously integrated
boost technique up to 50–56 Gy followed by surgery
and intraoperative radiation with 10–12 Gy. The pri-
mary endpoint is 5-year local control. Secondary end-
points include progression-free survival, overall survival
and toxicity. Due to slow accrual, an unplanned interim
analysis was recently performed after 27 patients with a
median f/u of 33 months [67]. Patients showed typical
features of retroperitoneal sarcomas with a median size
of 15 cm, mainly high grade lesions (82%), predominantly
liposarcomas (70%) and 15% already in recurrent situ-
ation. Neoadjuvant IMRT was completed as planned in
93%. Surgery was gross complete in all except one patient
but resulted in microscopically positive margins in 74%,
although contiguous organ resection was used in 96%.
IORT was performed as planned in 85% with a median
dose of 12 Gy using a median energy of 8 MeV. Local fail-
ures (defined as intraabdominal recurrence) were ob-
served in 7 patients (crude rate 26%), resulting in an
estimated 5-year local control rate of 72%. Recurrent situ-
ation was the only significant negative prognostic factor
(estimated 5-year local control 88% in primary situation).
Distant failure was the main reason for progression (5-
year DC 63%) with histology of leiomyosarcoma being the
only significant negative prognostic factor. Estimated 5-
year overall survival was 72%. Acute radiation related tox-
icity was quite acceptable (CTCAE 3.0 grade 3: 15%),
mainly haematological or gastrointestinal. Postoperative
complications were considerable (Clavien-Dindo grade ≥
3: 33%) with a relaparotomy rate of 15% but mainly related
to surgery. 30 day mortality was 0% but two patients died
in the prolonged postoperative period. Severe late toxicity
(CTCAE 3.0 grade 3) was very rare with 6% at 1 year and
0% at 2 years in evaluable patients.
Fig. 2 Treatment of retroperitoneal sarcoma according to RETRO-WTS trial [56, 67]
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In summary, the combination of preoperative EBRT,
surgery and IORT resulted consistently in high 5-year
local control rates of 51–83% in patients with retroperi-
toneal STS (see Table 2) [57, 67, 68, 70–73]. Those re-
sults seem to be superior to surgery alone or surgery
combined with EBRT at least with regard to local control
[52, 67, 74] and in some reports even to overall survival
[67, 68]. Further on, preoperative EBRT in combination
with IORT seems to be superior to the opposite combin-
ation with regard to local control and toxicity [67, 71, 74].
Some groups reported excellent central (infield IORT)
local control rates with acceptable toxicities using IORT
and postoperative EBRT [19, 52], but locoregional (ab-
dominal) control was rather poor [19], although the tox-
icity profile was superior to postoperative EBRT alone
[52]. This might reflect the general limitations of the post-
operative approach in target coverage/dose intensity and/
or the difficulties in adequately sparing adjacent organs at
risk (especially small bowel). In the randomized NCI trial,
severe chronic GI-toxicity (scored according to NCI-
IORT criteria) was found in 13% in the IORT + limited
EBRT arm versus 50% in the postoperative EBRT only
arm [52]. Krempien et al. [19] similarly described bowel
stenosis/fistula in 11% using IORT and postoperative
EBRT with moderate doses. Petersen et al. [57] observed
severe GI-toxicities (modified NCI-IORT criteria) in 12%
combining preoperative EBRT, surgery and IORT and
Roeder et al. [67] observed severe late toxicities (CTCAE
3.0) only in 6% (although with short follow-up) in their
prospective trial using preoperative IMRT, surgery and
IORT. Nevertheless, gastrointestinal structures should be
excluded from IORT fields whenever possible and ad-
equately spared during preoperative radiation therapy
using modern EBRT techniques. In the earlier mentioned
NCI trial, neuropathy was the major toxicity in the IORT
arm. While only 5% of the patient in the postoperative RT
only arm had neuropathy, it was found in 60% of the
IORT arm [52]. As known from IORT studies dealing with
colorectal cancer, high single doses (>15 Gy) during IORT
can be associated with a considerable risk for neuropathy
[53, 54]. In the NCI trial most patients received a single
dose of 20 Gy [52]. Further on, many patients had prob-
ably been treated with overlapping fields which would
results in even higher doses probably responsible for the
high neuropathy rate. In contrast, Petersen et al. [57] re-
ported only 10% severe neuropathy (modified NCI-IORT
criteria) avoiding overlapping fields and Krempien et al.
[19] also found only an 8% neuropathy rate (RTOG
criteria). In the prospective trial reported by Roeder et al.
[67] no severe neuropathy (CTCAE 3.0) was found after
restriction of the IORT dose to 12 Gy. Therefore overlap-
ping fields should be avoided and the IORT dose might be
restricted to 12 Gy especially if major nerves have to be
included. Finally ureter stenosis has been described
frequently in association with IORT in the retroperitoneal
space. Miller et al. [75] thoroughly analysed this issue
in an cohort of 138 patients comparing the risk for a
clinically apparent ureter stenosis (defined as needing
stenting, nephrostomy or surgery) irradiated ureter
and the non-irradiated ureter after surgery and IORT.
He observed a statistically increased 5-year incidence
of 41% in the irradiated ureters compared to 19% in
the non-irradiated ones. The risk was further clearly
dose-dependent. Therefore one should exclude the
ureters form the IORT area whenever possible or at
least limit the dose although one should keep in mind
that retroperitoneal surgery per se is associated with
a considerable risk for ureter stenosis. However, IOERT as
part of a multimodal approach offers excellent outcomes
in patient with retroperitoneal STS even in prognostic un-
favourable situations, especially if combined with pre-
operative EBRT. This approach seems more effective with
regard to local control than preoperative EBRT alone and
less harmful with regard to acute and late radiation related
toxicities than the opposite schedule without increasing
the postoperative complication rate.
Conclusion
In summary, the combination of limb-sparing surgery,
IORT and pre- or postoperative EBRT with moderate
doses consistently achieved excellent local control rates
in extremity STS which are at least comparable to ap-
proaches using EBRT alone but usually including patient
cohorts with higher proportions of unfavourable prog-
nostic factors. Further on, IORT containing approaches
resulted in very high limb preservation rates and good
functional outcome, probably related to the smaller high
dose volume. In retroperitoneal STS, the combination of
preoperative EBRT, surgery and IORT consistently
achieved high local control rates which seem superior to
surgery alone or surgery with EBRT at least with regard
to local control and in some reports even to overall sur-
vival. Further on, preoperative EBRT in combination
with IORT seems to be superior to the opposite combin-
ation with regard to local control and toxicity. No major
differences in wound healing disturbances or postopera-
tive complication rates can be observed with IORT com-
pared to non-IORT containing approaches. Neuropathy
of major nerves remains a dose limiting toxicity requir-
ing dose restrictions or exclusion from target volume.
Gastrointestinal structures and ureters should be ex-
cluded from the IORT area whenever possible and the
IORT volume should be restricted to the available
minimum. Nevertheless, IORT represents an ideal
boosting method if combined with EBRT enabling the
application of very high doses with low toxicities
which should be further evaluated preferably in pro-
spective randomized trials.
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Abbrevations
ADL: Activities of daily living; Ccm: Cubic centimeter; Cm: Centimeter;
CTCAE: Common Toxicity Criteria for Adverse events; EBRT: External beam
radiation therapy; f/u: Follow up; HDR: High dose rate; GI: Gastrointestinal;
Gy: Gray; IOERT: Intraoperative electron radiation therapy; IORT: Intraoperative
radiation therapy; IMRT: Intensity-modulate radiation therapy; ISIORT: International
Society of Intraoperative Radiation Therapy; LC: Local control; LINAC: linear
accelerator; MeV: Mega electron volts; MGH: Massachusetts General
Hospital; NCI: National Cancer Institute; NCIC: National Cancer Institute
Canada; NCI-IORT criteria: Toxicity criteria developed by the NCI IORT
working group; OS: Overall survival; Pts: Patients; RT: Radiation therapy;
RTOG: Radiation Therapy Oncology Group; STS: Soft tissue sarcoma;
US: United States; WHO: World health organization
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